Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis [0.03%]
docetaxel在非小细胞肺癌治疗中的应用进展及分析
Matthew A Gubens,Heather A Wakelee
Matthew A Gubens
Docetaxel, a semisynthetic taxane, was the first agent to show efficacy in the second-line treatment of non-small cell lung cancer (NSCLC), and has since become a mainstay of NSCLC therapy. We review its mode of action, pharmacology, toxici...
Shifting the paradigm for maintenance therapy in advanced non-small-cell lung cancer [0.03%]
晚期非小细胞肺癌维持治疗范式的转变
Barbara Melosky
Barbara Melosky
The standard of care in metastatic non-small-cell lung cancer (NSCLC) is to treat patients with a platinum doublet for 4 to 6 cycles and to offer second-line therapy upon progression. Maintenance therapy in NSCLC is defined as a therapeutic...
Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer [0.03%]
吉非替尼治疗非小细胞肺癌：经受欧洲时间的考验？
Caroline Wilson,Sarah J Danson
Caroline Wilson
Lung cancer is the most common cancer worldwide, with 1.3 million new cases diagnosed every year. Non-small-cell lung carcinoma (NSCLC) has previously had a very poor prognosis with few effective therapies; however, research has identified ...
Manish Shanker,David Willcutts,Jack A Roth et al.
Manish Shanker et al.
Resistance to chemotherapy drugs is a major problem in cancer treatment. Scientific advances made in the last two decades have resulted in the identification of genes and molecular signaling mechanisms that contribute to drug resistance. Th...
Shin Ogita,Antoinette J Wozniak
Shin Ogita
Metastatic nonsmall cell lung cancer (NSCLC) is a debilitating and deadly disease with virtually no chance for long-term survival. Chemotherapy has improved both survival and quality of life for patients with advanced disease. Overall survi...
Maintenance therapy for metastatic non-small-cell lung cancer - the role of pemetrexed [0.03%]
非小细胞肺癌脑转移的维持治疗-培美曲塞的作用
Youval Katz,Robert A Somer
Youval Katz
Over the last several years, we have greatly enhanced our understanding of tumor biology and have now integrated novel and molecular-targeted therapies into front-line treatment for locally advanced and metastatic non-small-cell lung cancer...
Joshua D Salvi
Joshua D Salvi
Emerging treatments in lung cancer - targeting the RLIP76 molecular transporter [0.03%]
肺癌的新疗法-作用于分子转运体RLIP76
Lawrence E Goldfinger,Seunghyung Lee
Lawrence E Goldfinger
Multidrug resistance in lung cancer cells is a significant obstacle in the treatment of lung cancer. Resistance to chemotherapeutic agents is often the result of efflux of the drugs from cancer cells, mediated by adenosine triphosphate (ATP...